Know Cancer

forgot password

Feasibility and Outcome of Cyberknife® Precision Hypofractionated Radiosurgery for the Curative Management of Non-Small Cell Lung Cancer

Phase 1
18 Years
Open (Enrolling)
Lung Cancer

Thank you

Trial Information

Feasibility and Outcome of Cyberknife® Precision Hypofractionated Radiosurgery for the Curative Management of Non-Small Cell Lung Cancer


- To establish the maximum tolerated dose of CyberKnife® hypofractionated stereotactic
radiosurgery in patients with medically inoperable, stage I or II non-small cell lung

- To establish the relationship between PET response and local control and survival using
fludeoxyglucose F 18 PET/CT imaging before treatment and at 1, 3, 6, and 12 months
after treatment.

OUTLINE: Patients undergo placement of 3 gold fiducial markers by CT-guidance or
bronchoscopy. Patients then undergo CyberKnife® hypofractionated stereotactic radiosurgery
over 45-120 minutes twice weekly for 2 weeks.

Patients undergo fludeoxyglucose F 18 PET/CT scan at baseline and at 1, 3, 6, and 12 months
after completion of treatment.

After completion of study treatment, patients are followed periodically for up to 4 years.

Inclusion Criteria


- Histologically confirmed non-small cell lung cancer

- Stage I or II disease (T1-3, N0, M0)

- T2 or T3 tumor ≤ 5 cm

- No T3 tumors involving the central chest or mediastinum (only chest wall
involvement allowed)

- No tumor within or touching the proximal bronchial tree, defined as a volume of 2 cm
in all directions around the proximal bronchial tree (carina, right and left main
stem bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle
lobe bronchus, lingular bronchus, right and left lower lobe bronchi)

- Tumor deemed technically resectable, in the opinion of an experienced thoracic
surgeon, AND patient deemed "medically inoperable"

- No suspected nodal metastasis that cannot be falsified by mediastinoscopy (i.e.,
hilar or mediastinal nodes that are either fludeoxyglucose F 18 [FDG]-avid or measure
> 1 cm in short axis diameter on CT scan)

- Patients with FDG-avidity in mediastinal lymph nodes are eligible provided they
are able to undergo mediastinoscopy to confirm N0 status


- ECOG performance status 0-2

- Not pregnant or nursing

- Fertile patients must use effective contraception during and for ≥ 6 months after
completion of study treatment

- No history of contrast allergy

- No psychological issues that would preclude the completion of study treatment


- No prior radiotherapy or chemotherapy

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To establish the maximally tolerated dose of CyberKnife® radiosurgery in patients with medically inoperable clinical Tl-3 N0 M0 NSCLC

Outcome Time Frame:

6 weeks

Safety Issue:


Principal Investigator

Lisa A. Kachnic, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Boston Medical Center


United States: Food and Drug Administration

Study ID:




Start Date:

January 2009

Completion Date:

March 2014

Related Keywords:

  • Lung Cancer
  • stage I non-small cell lung cancer
  • stage II non-small cell lung cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



Boston University Cancer Research Center Boston, Massachusetts  02118